BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Sarah-Jane Dawson; Nikitsa Makretsov; Fiona Blows; Kristy Driver; Elena Provenzano; John Le Quesne; Laura Baglietto; Gianluca Severi; Graham Giles; Catriona Ann McLean; Grace Callagy; Andrew Green; Ian Ellis; Karen Gelmon; Gulisa Turashvili; S Leung; S Aparcio; David Huntsman; Carlos Caldas; Paul Pharoah

doi:10.1038/sj.bjc.6605736

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Sarah-Jane Dawson, Nikitsa Makretsov, Fiona Blows, Kristy Driver, Elena Provenzano, John Le Quesne, Laura Baglietto, Gianluca Severi, Graham Giles, Catriona Ann McLean, Grace Callagy, Andrew Green, Ian Ellis, Karen Gelmon, Gulisa Turashvili, S Leung, S Aparcio, David Huntsman, Carlos Caldas, Paul Pharoah

Research output: Contribution to journal › Article › Research › peer-review

258 Citations (Scopus)

Abstract

Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2.

Original language	English
Pages (from-to)	668 - 675
Number of pages	8
Journal	British Journal of Cancer
Volume	103
Issue number	5
DOIs	https://doi.org/10.1038/sj.bjc.6605736
Publication status	Published - 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6605736

Cite this

Dawson, S.-J., Makretsov, N., Blows, F., Driver, K., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G., McLean, C. A., Callagy, G., Green, A., Ellis, I., Gelmon, K., Turashvili, G., Leung, S., Aparcio, S., Huntsman, D., Caldas, C., & Pharoah, P. (2010). BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British Journal of Cancer, 103(5), 668 - 675. https://doi.org/10.1038/sj.bjc.6605736

@article{02d0aa616e864bb29b79b10a505ab7c8,

title = "BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received",

abstract = "Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2.",

author = "Sarah-Jane Dawson and Nikitsa Makretsov and Fiona Blows and Kristy Driver and Elena Provenzano and {Le Quesne}, John and Laura Baglietto and Gianluca Severi and Graham Giles and McLean, {Catriona Ann} and Grace Callagy and Andrew Green and Ian Ellis and Karen Gelmon and Gulisa Turashvili and S Leung and S Aparcio and David Huntsman and Carlos Caldas and Paul Pharoah",

year = "2010",

doi = "10.1038/sj.bjc.6605736",

language = "English",

volume = "103",

pages = "668 -- 675",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "5",

}

Dawson, S-J, Makretsov, N, Blows, F, Driver, K, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G, McLean, CA, Callagy, G, Green, A, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparcio, S, Huntsman, D, Caldas, C & Pharoah, P 2010, 'BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received', British Journal of Cancer, vol. 103, no. 5, pp. 668 - 675. https://doi.org/10.1038/sj.bjc.6605736

TY - JOUR

T1 - BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

AU - Dawson, Sarah-Jane

AU - Makretsov, Nikitsa

AU - Blows, Fiona

AU - Driver, Kristy

AU - Provenzano, Elena

AU - Le Quesne, John

AU - Baglietto, Laura

AU - Severi, Gianluca

AU - Giles, Graham

AU - McLean, Catriona Ann

AU - Callagy, Grace

AU - Green, Andrew

AU - Ellis, Ian

AU - Gelmon, Karen

AU - Turashvili, Gulisa

AU - Leung, S

AU - Aparcio, S

AU - Huntsman, David

AU - Caldas, Carlos

AU - Pharoah, Paul

PY - 2010

Y1 - 2010

N2 - Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2.

AB - Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2.

UR - http://www.nature.com/bjc/journal/v103/n5/pdf/6605736a.pdf

U2 - 10.1038/sj.bjc.6605736

DO - 10.1038/sj.bjc.6605736

M3 - Article

SN - 0007-0920

VL - 103

SP - 668

EP - 675

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 5

ER -

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Abstract

UN SDGs

Access to Document

Other files and links

BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (British Journal of Cancer (2010) 103 (668675) Doi:10.1038/sj.bjc.6605736)

Cite this